This is the first time the FDA has sought to expand its list of compoundable substances since finalizing the criteria it will use to determine which bulk products can be used under Section 503A of the Federal Food, Drug and Cosmetic Act.
The five drug substances the FDA proposed adding to the list are glutaraldehyde, glycolic acid, L-citrulline, pyruvic acid and trichloroacetic acid.
The FDA also determined that another 26 bulk drug substances are not appropriate for compounding under the FD&C Act.
Last week, the FDA also identified nine bulk drug substances it says should not be compounded by outsourcing facilities under section 503B of FD&C Act after determining there is no clinical need for those substances to be compounded.
Read the full report here.
More articles on pharmacy:
FDA approves AbbVie’s $59K rheumatoid arthritis drug
Teva launches generic version of EpiPen for kids
American Regent boosted price of essential hospital product by 1,300%
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.